In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease),

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market. Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 receptor agonists used most commonly to treat type II diabetes.

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed to those with Type 2 diabetes, it is also used for weight loss. “I was not able to get the weight off myself,

THESE MEDICATIONS ARE MOSTLY KNOWN FOR TREATING DIABETES AND OBESITY.. BUT THE F-D-A HAS APPROVED THEM FOR PREVENTING HEART DISEASE AFTER STUDIES LAST FALL. THAT SHOWED ABOUT A 20% REDUCTION IN CARDIOVASCULAR EVENTS DR.

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.

Denmark’s Novo Nordisk saw its shares rise as much as 13% to 659.20 kroner this morning, after it announced top-line results from a Phase Ib/IIa clinical trial with amycretin once weekly subcutaneous (SC) administration.

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 products by mimicking a hormone in the body that provides a satiated feeling, which curbs hunger, but adds a different hormone in the pancreas.

Colin Jost recalled the time he was contestant on a college episode of "The Weakest Link" and the "humiliating" wrong answer he gave during the competition.